Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11121105 | 0.78 | TRPM8 (0.36) | ALDH1A1 | |
| SCHEMBL11595949 | 0.77 | — | — | |
| SCHEMBL6750640 | 0.75 | TSHR (0.50) | TSHRTDP1 | |
| SCHEMBL28293652 | 0.75 | CYP2C19 (0.32) | CYP2C19LMNATSHRGABRR1GABBR2 | |
| SCHEMBL28293605 | 0.75 | ALDH1A1 (0.35) | CYP2C19LMNATDP1ALDH1A1 | |
| SCHEMBL18979001 | 0.75 | LMNA (0.36) | CYP2C19LMNAALDH1A1GABRR1GABBR2 | |
| SCHEMBL14818474 | 0.73 | LAP3 (0.35) | — | |
| SCHEMBL14818475 | 0.73 | LAP3 (0.35) | — | |
| SCHEMBL11159927 | 0.73 | GABRR1 (0.38) | GABRR1 | |
| SCHEMBL11742389 | 0.73 | CYP2C19 (0.31) | CYP2C19LMNAGABRR1GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118126080-A | Chiral gamma-carbonyl phosphate derivative and preparation method and application thereof | 武汉大学 | 2024-06-04 | — | — | CN | disclosed |
| EP-3689886-A1 | BCL-2/BCL-XL INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | The Regents of The University of Michigan (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-2945940-B1 | BCL-2/BCL-XL INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | UNIV MICHIGAN REGENTS (US) | 2020-07-15 | — | — | EP | disclosed |
| US-9403856-B2 | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-08-02 | — | — | US | disclosed |
| CN-105246882-A | BCL-2/Bcl-xL inhibitors and methods of treatment using the same | UNIV MICHIGAN | 2016-01-13 | — | — | CN | disclosed |
| US-20150336994-A1 | BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2945940-A1 | BCL-2BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents Of The University Of Michigan (US) | 2015-11-25 | — | — | EP | disclosed |
| US-9096625-B2 | BCL-2/BCL-XL inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2014113413-A1 | BCL-2BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20140199234-A1 | BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-07-17 | — | — | US | disclosed |
| US-20040224234-A1 | for use in automobiles, sensors, electrochromic windows, displays, capacitors and ion-conducting films | BASF AKTIENGESELLSCHAFT (DE) | 2004-11-11 | — | — | US | disclosed |
| CN-1390365-A | Wet-on-wet coating method for producing composite bodies that are suitable for use in lithium ion batteries | BASF AG (DE) | 2003-01-08 | — | — | CN | disclosed |
| US-6475663-B1 | Compositions suitable for electrochemical cells | BASF AKTIENGESELLSCHAFT (DE) | 2002-11-05 | — | — | US | disclosed |
| US-5532402-A | Process for producing optically active hydroxyalkylphosphonates | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-07-02 | — | — | US | disclosed |
| US-4022757-A | Dicarbamic acid diesters containing phosphorus | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-10 | — | — | US | disclosed |
| US-3962378-A | Preparation of phosphorus-organic esters | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336994-A1 | BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BCL2, BCL2L2, BCL2L1 | CYP2C19 4806/4885LMNA 1522/4885TSHR 4319/4885 |
| US-20140199234-A1 | BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BCL2, BCL2L2, BCL2L1 | CYP2C19 4806/4885LMNA 1522/4885TSHR 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.